NASDAQ: IVFInvo Fertility Inc Stock
$1.31-0.11 (-7.75%)
Updated Jun 13, 2025
IVF Price
$1.31
Fair Value Price
N/A
Market Cap
$2.82M
52 Week Low
$1.30
52 Week High
$17.04
P/E
-0.04x
P/B
0.84x
P/S
0.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.59M
Earnings
-$24.90M
Gross Margin
41.6%
Operating Margin
-360.1%
Profit Margin
-381.5%
Debt to Equity
7.32
Operating Cash Flow
-$6M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IVF Overview
INVO Bioscience Incorporated is a commercial-stage company developing tassisted reproductive technologies intended to make fertility care accessible to people around the world. The company's flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place within the woman's body. Its treatment solution is an intravaginal culture technique which incubates both oocytes and sperm during fertilization and early embryo development. INVO Bioscience was founded in 2007 and is headquartered in Sarasota, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IVF's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
IVF
Ranked#108 of 108
Ranked#108 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important IVF news, forecast changes, insider trades & much more!
IVF News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IVF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IVF is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IVF is good value based on its book value relative to its share price (0.84x), compared to the US Medical Devices industry average (3.99x)
P/B vs Industry Valuation
IVF is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IVF due diligence checks available for Premium users.
Valuation
IVF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
35.6x
Market
31.36x
IVF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.84x
Industry
3.99x
IVF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IVF's financial health
Profit margin
Revenue
$1.6M
Net Income
-$17.4M
Profit Margin
-1,063%
IVF's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IVF's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$31.7M
Liabilities
$24.4M
Debt to equity
7.32
IVF's short-term liabilities ($18.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IVF's long-term liabilities ($5.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IVF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IVF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.5M
Investing
-$14.7k
Financing
$3.7M
IVF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IVF vs Medical Device Stocks
Invo Fertility Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.